Symbiotic bacteria | Larval stages | Moratality rates (%) after treatment | ||
---|---|---|---|---|
24 h | 48 h | 72 h | ||
Contact | ||||
X. b. MCB-8 | 1st/2nd | 5.0Aa | 35.0Ab | 55.0Ac |
P. l. AVB-15 | 2.5Aa | 42.5Ab | 57.5Ab | |
X. b. KBC-4 | 0.0Aa | 32.5Ab | 42.5Bb | |
X. b. MCB-8 | 3rd/4th | 0.0Aa | 25.0Ab | 45.0Ac |
P. l. AVB-15 | 0.0Aa | 22.5Ab | 30.0Bb | |
X. b. KBC-4 | 0.0Aa | 17.5Ab | 30.0Bb | |
Oral | ||||
X. b. MCB-8 | 1st/2nd | 0.0Aa | 10.0Aab | 15.0Ab |
P. l. AVB-15 | 0.0Aa | 7.5Aa | 15.0Ab | |
X. b. KBC-4 | 0.0Aa | 12.5Ab | 20.0Ab | |
X. b. MCB-8 | 3rd/4th | 0.0Aa | 2.5Aa | 5.0Aa |
P. l. AVB-15 | 0.0Aa | 2.5Aa | 7.5Aa | |
X. b. KBC-4 | 0.0Aa | 5.0Aa | 7.5Aa |